New molecular platform to access intracellular targets across a broad range of tumor cell types
Opens up new range of therapeutic opportunities for difficult-to-treat cancers
INGELHEIM, Germany & BERLIN -- (BUSINESS WIRE) --
Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics. Further details of the acquisition are not being disclosed.
“Boehringer Ingelheim’s collaboration with nanoPET Pharma has the potential to eliminate the hurdle that many cancer biologics face: getting access to targets inside tumor cells,” said Norbert Kraut, Ph.D., Global Head of Cancer Research, Boehringer Ingelheim. “We will use ICD’s MacroDel technology to develop first-in-class potential drug candidates for intracellular targets across a variety of tumor types, for the benefit of patients who so far have no or only inadequate treatment options.”
Engineered proteins and peptides offer great potential to block protein-protein interactions inside cancer cells, but their large size is generally assumed to prevent intracellular delivery. ICD’s MacroDel technology exploits transporter proteins in the cell membrane to deliver such drug candidates inside tumor cells. This opens up therapeutic targets that would be otherwise inaccessible.
“nanoPET Pharma looks forward to collaborating with Boehringer Ingelheim on the pre-clinical refinement of ICD’s MacroDel to achieve effective intracellular delivery of macromolecules such as peptides and proteins,” said Andreas Briel, Ph.D., Managing Director of nanoPET Pharma GmbH. “We are excited to contribute to Boehringer Ingelheim’s discovery and development of innovative medicines for patients in need.”
More about MacroDel
Tree-like highly branched molecules known as dendrimers form a fundamental component of the MacroDel platform. The size, shape and electrical charge of this structure permit it to grasp large therapeutic biological molecules. After binding with the biologic, the resulting compound selectively interacts with transporter proteins known to be highly expressed on tumor cell wall membranes. These transporters help “carry” the compound through the membrane and into the cell. The medicinal cargo is then in position to disrupt the disease process in a precise manner at a molecular level.
A prior investment from Boehringer Ingelheim’s Venture Fund (BIVF) supported ICD’s development of the MacroDel technology. The BIVF strategically invests in groundbreaking therapeutics-focused biotechnology companies to enable development of their technologies for therapeutic applications that have potential for strategic partnerships with Boehringer Ingelheim or other pharmaceutical partners.
Advanced Energy宣布推出超宽温度范围的高精度
新的CloudBlue Connect提供能统一多渠道
孙建锋——德艺双馨艺术家献礼建党99周年
联想研究发现企业可采取三个步骤来实现超越界
非营利性融资平台Heroe5推出The
Biban 2023开幕当天签署超过25项协议
Lightbits扩大私有、混合和边缘部署的横向扩展分
彰显出MSCI在提高环境、社会与治理(ESG)透明度
Synergis Adept在G2的2022年春季报告中
渤海中学北校区高一第一次家长学校交流大会隆
Kyriba’s Currency Impact
Eagle Eye Networks和Brivo
穆迪分析借助AI支持功能增强CreditEdge
Sintavia聘请Brian Haggenmiller
爱科与博世、巴斯夫xarvio数字农业解决方案及
上饶人的“尔滨”冰雪世界
国际土著语言大会定于6月在不列颠哥伦比亚省
ROSEN鼓励损失超过10万美元的Citrix
阳信县第二高级中学2019年十大工作亮点
OCF成员认证首批通用云接口(UCI)平台
艾贝特亮相2020中国国际光电博览会,共鉴光电
2019年5个灸手可热的文化旅游热点
蒙碟儿铜锅涮 一个有历史的火锅落户中卫市
Personalis宣布与MapKure合作